Prsentation PowerPoint

1
BioWin, an open cluster in a challenging global
health environment
DAMIEN DALLEMAGNEGeneral Manager
2
Wallonia, a strong network in health biotechnology

• 100 biotech/pharma companies , mostly SMEs
  (turnover of 2,7 billion 10,000 jobs) world
  leaders such as
• 125 research units from 3 universities 19,000
  students in biomed sciences 5,000 PhDs in
  biomed sciences
• Several prestigious research centers (Ludwig
  Institute, GIGA, Institute for Medical
  Immunology, .)
• 15 higher education schools and training centres
• 7 university hospitals,1 business network
  dedicated to clinical research (ARESA), several
  biotech incubators, a European platform for
  biologistics,

3
Biotech in Wallonia main fields of activity

• Focused on human health gt Red biotech 80 of
  biotech in Walloniagt Medical Technologies
• Pharmacy/ Biopharmacy
• Diagnostics
• Medical Imaging
• Cell Therapy
• Medical imaging
• Medical devices
• Medical equipments
• Support services to industry

R DPreclinical
Clinical Research
ProductDevelt.
RegulatoryMarketingSales
Production
Biologistics
From bench to market!
4
Health biotechnology in Wallonia 3 major hubs
Gosselies
5
BioWin 3 strategic missions as a cluster

• Stimulate the regional economy
• Increase international attractiveness
• Stimulate job creation

6
BioWins strategy 5 axis of developement
Vision 2015
7
Three major drivers of development

• Excellence of research
• Outstanding human capital
• International attractiveness

special focus on the needs of SMEs !
8
Excellence in Research Innovative RD Projects

• Yearly calls for RD projects since 2006
• 50 RD projects submitted ? 16 RD approved and
  financed
• average project budget of 3-4 million
• minimum consortium 2 companies 2 academic
  labs
• selection by an independent international jury
  of experts
• 16 RD projects involving 25 SMEs, 5 large
  companies,
• 40 university labs and 2 research centers
• Therapeutic areas cancer, inflammation, brain
  diseases
• Technology domains biomarkers, diagnostics,
  immunotherapy, cell therapy, drug delivery,
  devices equipments

9
Outstanding human capital
Training courses 3-5 days specific training
modules for people at work 6-8 months training
for unemployed ? biotech technicians Bridges
between universities and enterprises In-company
traineeships for students ? working on
innovation projects
10
International attractiveness

• BioWin is actively present on the international
  scene
• BioWin Day (Liège Belgium)
• BioSquare (Lyon - France)
• Biomedica (Liège Belgium)
• Bio US (Atlanta USA)
• Biotech China (Shangai - China)
• EuroBio (Lille France)
• Medica (Dusseldörf Germany)

With the support of
11
International attractiveness

• BioWin promotes international partnerships

• Collaborative projects (RD, training)
• European networking
• Worldwide connections
• Networking

Atlantic Biotherapies
EuroBioMed
Texas AM
Kobe-Kansai / Japan
ERRIN
12
Key challenges for 2009 to 2015

• Support the creation of spin-offs
• Maximize the valorization of IP originating
  from BioWin projects
• Consolidate international collaborations
• Exchange researchers
• Attract new talents
• Participate into European programs (FP7, IMI,
  ERA-Net, )

13
Contacts BioWin asbl
Damien Dallemagne Managing Director Sylvie
Ponchaut Scientific DirectorMarianne Ghyoot
Senior RD Project Coordinator Frédéric Druck
Comm Interntl Relations Director Point
Centre Avenue Georges Lemaître 19 B-6041
Gosselies Belgium T. 32 71/376.386 contact_at_biowi
n.org http//www.biowin.org